Modis raises $30M series A for mitochondrial disorders

F-Prime Capital Partners and OrbiMed Advisors led a $30 million series A round for rare genetic disease company Modis Therapeutics Inc. (Oakland, Calif.). The round also included founding investor Aceras Life Sciences and new investor Osage University Partners.

Modis also hired Joshua Grass as president and CEO. Grass was previously entrepreneur-in-residence at F-Prime and SVP of business and corporate development at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)...